DOCSLIB.ORG

Investigating the Effect of Emetic and Aversive Compounds on Dictyostelium Identifies a Novel Non-Sentient Model for Bitter Tastant Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investigating the Effect of Emetic and Aversive Compounds on Dictyostelium Identifies a Novel Non-Sentient Model for Bitter Tastant Research Investigating the effect of emetic and aversive compounds on Dictyostelium identifies a novel non-sentient model for bitter tastant research Steven Jann Robery Research thesis submitted for the degree of Doctor of Philosophy at Royal Holloway University of London in July 2013 Declaration of Authorship I, Steven Robery, hereby declare that this thesis and the work presented in it is entirely my own. Where I have consulted the work of others, this is always clearly stated. Signed: Date: 2 Acknowledgements First and foremost, I would like to thank my supervisors, Professor Robin Williams and Professor Paul Andrews. I would like to thank Robin for providing me with the support and direction he has given me over the past few years, as well as teaching me to critique my own work to make me a better scientist. I would like to thank Paul for providing me with support, advice and passion throughout my PhD. Your meetings were always inspirational. I would also like to thank my laboratory colleagues for all of the help, support and banter whilst I have been at Royal Holloway. Secondly, I would like to thank my funding body, Universities Federation for Animal Welfare. Without you I would not have been given a PhD and been able to undertake this exciting project, nor would I have been able to contribute to the world of science in the way that I have. I would also like to thank my friends and family for all of the support you have given me over the years. In particular I would like to thank my girlfriend Annabelle, for putting up with me and for providing me with laughs and generally being there for me when I needed her to be. I would also like to thank my parents, Peter and Elisabeth, as well as my sister, Nina for providing me with all the support and encouragement I needed. I would also like to thank my all my friends, providing me with the banter and encouraging me to “get a move on” and complete my PhD. Finally, I can’t forget my dog, Plato, who let me know time and again whilst I was writing that it is time to clear my mind and go for a much needed walk. 3 Abstract Nausea and vomiting are common but serious side effects associated with many therapeutic drugs. Whilst the physiological mechanisms behind the generation of the vomiting response are well characterised, the range of emetic stimuli that can generate the response are poorly understood. The potential of using Dictyostelium discoideum, a eukaryotic amoeba, as a model for predicting emetic liability was examined in this thesis. The effects of a range of known emetic and aversive compounds on Dictyostelium cell behaviour was investigated, resulting in the identification of a small number that strongly inhibited cell migration in a concentration-dependent and reversible manner. These active compounds included a range of bitter compounds and the pungent tastant, capsaicin. A Dictyostelium mutagenesis screen was then used to identify genes controlling sensitivity to bitter tastants. This screen identified a mutant containing a disrupted grlJ gene as showing partial resistance to phenylthiourea in growth and behavioural changes in movement. GrlJ is a G- protein coupled receptor that regulates a phenylthiourea-dependent effect by inhibition of a phosphatidylinositol (PIP3) signalling pathway. A search for proteins sharing homology to GrlJ identified an uncharacterised GABAB-like receptor, Q8NHA5, involved in the detection of phenylthiourea in Dictyostelium. This thesis has therefore identified Dictyostelium as a potentially useful model for the identification of bitter and pungent tastants. In addition, this thesis has identified the Dictyostelium protein, GrlJ, as well as an uncharacterised human protein, Q8NHA5, involved in the detection of the bitter tastant, phenylthiourea. 4 Table of Contents Acknowledgements.......................................................................................... 3 Abstract ............................................................................................................... 4 List of Figures and Tables ................................................................................. 10 Abbreviations .................................................................................................... 14 Chapter 1 .......................................................................................................... 17 1.1. Nausea and Vomiting........................................................................... 18 1.2. Physiology of Nausea and Vomiting .................................................... 19 1.2.1. Pre-ejection phase ........................................................................ 19 1.2.2. Ejection phase ............................................................................... 20 1.2.3. Post-ejection phase ....................................................................... 20 1.3. Pharmacology of Nausea and Vomiting ............................................... 20 1.4. Emetic Compounds ............................................................................. 23 1.4.1. Ligand gated ion channels ........................................................... 24 1.4.2. Ion Channels ................................................................................. 27 1.4.3. G Protein-Coupled Receptors ....................................................... 28 1.4.4. Transporters and Enzymes ........................................................... 34 1.5. Animal Models in Emetic Research ..................................................... 35 1.6. Dictyostelium discoideum .................................................................... 38 1.7. Dictyostelium as a Biomedical Model .................................................. 40 1.7.1. Channels and Receptors in Dictyostelium ........................................... 42 1.7.2. GABAB-like Receptors ................................................................... 43 1.7.3. cAMP Receptors ........................................................................... 43 1.8. Dictyostelium movement ...................................................................... 44 1.8.1. Detection of cAMP ......................................................................... 44 1.8.2. F-actin polymerisation ................................................................... 46 1.8.3. The Phosphatydylinositol-3-kinase Pathway ................................. 48 1.8.4. Target of Rapamycin complex 2 .................................................... 52 1.8.5. The Phospholipase A2 Pathway .................................................... 53 1.8.6. Alternative Amplification Pathways................................................ 54 1.9. Aims of this work .................................................................................. 56 Chapter 2 .......................................................................................................... 57 2.1. Materials ................................................................................................. 58 2.1.1. General reagents ............................................................................. 58 5 2.1.1.1. Reagents purchased from Sigma-Aldrich Co. Ltd (Dorset, England) 58 2.1.1.2. Reagents purchased from other suppliers ........................................ 58 2.1.1.3. Antibiotics ......................................................................................... 59 2.1.1.4. Molecular weight standards .............................................................. 59 2.1.1.5. Restriction enzymes ......................................................................... 59 2.1.1.6. Other enzymes ................................................................................. 60 2.1.1.7. Antibodies ......................................................................................... 60 2.1.1.8. Kits .................................................................................................... 60 2.1.1.9. Escherichia coli (E.coli) strains ......................................................... 61 2.1.1.10. Primers ........................................................................................... 61 2.1.1.11. Equipment....................................................................................... 61 2.2. Methods .................................................................................................. 62 2.2.1. Dictyostelium methods ................................................................... 62 2.2.1.1. Cell culture ........................................................................................ 62 2.2.1.2. Growth curve assays ........................................................................ 62 2.2.1.3. Colony formation assays .................................................................. 63 2.2.1.4. Development assays ........................................................................ 63 2.2.1.5. Spore shape ..................................................................................... 63 2.2.1.6. Motility assays .................................................................................. 64 2.2.1.7. Random cell movement assays ........................................................ 64 2.2.1.8. Cell viability assays ........................................................................... 65 2.2.1.9. PHCRACGFP global stimulation experiments...................................... 65 2.2.1.10. PIP3 mass ELISA ...........................................................................
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Transcriptional Profiling Identifies the Lncrna PVT1 As a Novel Regulator of the Asthmatic Phenotype in Human Airway Smooth Muscle
    Accepted Manuscript Transcriptional profiling identifies the lncRNA PVT1 as a novel regulator of the asthmatic phenotype in human airway smooth muscle Philip J. Austin, MSc, Eleni Tsitsiou, PhD, Charlotte Boardman, MD, Simon W. Jones, PhD, Mark A. Lindsay, PhD, Ian M. Adcock, PhD, Kian Fan Chung, MD PhD, Mark M. Perry, PhD PII: S0091-6749(16)30571-1 DOI: 10.1016/j.jaci.2016.06.014 Reference: YMAI 12203 To appear in: Journal of Allergy and Clinical Immunology Received Date: 5 April 2016 Revised Date: 24 May 2016 Accepted Date: 13 June 2016 Please cite this article as: Austin PJ, Tsitsiou E, Boardman C, Jones SW, Lindsay MA, Adcock IM, Chung KF, Perry MM, Transcriptional profiling identifies the lncRNA PVT1 as a novel regulator of the asthmatic phenotype in human airway smooth muscle, Journal of Allergy and Clinical Immunology (2016), doi: 10.1016/j.jaci.2016.06.014. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT 1 Transcriptional profiling identifies the lncRNA PVT1 as a novel 2 regulator of the asthmatic phenotype in human airway smooth muscle 3 4 Philip J. Austin MSc 1, Eleni Tsitsiou PhD 2, Charlotte Boardman MD 1, Simon W.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar Et Al
    USOO9347934B2 (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar et al. (45) Date of Patent: May 24, 2016 (54) ASSAYS FOR IDENTIFYING COMPOUNDS 2008, OO38739 A1 2/2008 Li et al. THAT MODULATE BITTERTASTE 2008/0167286 A1* 7/2008 Gopalakrishnan et al. ........................ 514,21016 (71) Applicants: CHROMOCELL CORPORATION, 2010/01298.33 A1* 5/2010 Brune et al. ................. 435/721 North Brunswick, NJ (US); KRAFT FOODS GROUP BRANDS LLC, FOREIGN PATENT DOCUMENTS Northfield, IL (US) CN 1341632 A 3, 2002 CN 101583717 A 11, 2009 (72) Inventors: Kambiz Shekdar, New York, NY (US); CN 101828.111 A 9, 2010 Purvi Manoj Shah, Bridgewater, NJ WO WO-0038536 A2 7, 2000 WO WO-2004O29087 4/2004 (US); Joseph Gunnet, Flemington, NJ WO WO-2006053771 A2 5, 2006 (US); Jane V. Leland, Wilmette, IL WO WO-2007002026 A2 1/2007 (US); Peter H. Brown, Glenview, IL WO WO-2008057470 5, 2008 (US); Louise Slade, Morris Plains, NJ WO WO-2008119.195 A1 10, 2008 (US) WO WO-20081191.96 10, 2008 WO WO-20081191.97 10, 2008 (73) Assignees: Chromocell Corporation, North W WSi. A2 1929 Brunswick, NJ (US); Kraft Foods WO WO-2010O886.33 8, 2010 Group Brands LLC, Northfield, IL WO WO-2010O99983 A1 9, 2010 (US) WO WO-2013022947 2, 2013 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Bachmanov et al., Taste Receptor Genes, 2007, 27:389-414.* Behrens et al., Structural Requirements for Bitter Taste Receptor (21) Appl.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Alissa L. Allen1, John E. Mcgeary2, and John E. Hayes1
    Bitterness of the non-nutritive sweetener Acesulfame Potassium varies with polymorphisms in TAS2R9, TAS2R31 and TAS2R38. Alissa L. Allen1, John E. McGeary2, and John E. Hayes1 1 Department of Food Science, College of Agricultural Sciences, The Pennsylvania State University, University Park, PA. 2 Providence Veterans Affairs Medical Center, Providence, RI Background Results Finding 4: Aggregate Genetic Bitterness Score predicts • Sweetness is innately liked by humans (reviewed by (Steiner, Glaser et al. Finding 1: Variation in the TAS2R9 Val187Ala allele the bitterness of AceK 2001)), even prior to birth (Snoo 1937). Many highly liked foods contain high predicts AceK bitterness endogenous amounts of natural sugars, or have sugars or other sweeteners added during processing. However, due to health risks such as cardiovascular disease, diabetes and obesity (Hill and Prentice 1995; Howard and Wylie- Rosett 2002), there has been a demand for reduced added-sugar in foods. To retain desired levels of sweetness while reducing calories, bulk carbohydrates are often replaced with non-nutritive sweeteners. • Acesulfame potassium (AceK) was approved by the US Food and Drug Administration for use in dry foods in 1994; approval as a general-purpose sweetener followed in 2002. However, in addition to eliciting sweet sensations, many non-nutritive sweeteners also have objectionable side tastes, such as bitterness, that are experienced by some individuals but not others. Thus, better understanding of the mechanisms underlying this variability may facilitate improved product formulation, with the potential to substantially impact health and wellness. Figure 4: Correlation between Perceived Bitterness of AceK and the Aggregate • Numerous studies have demonstrated that the perception of bitter taste in Figure 1: Effect of TAS2R9 polymorphisms on the bitterness and sweetness of AceK and bitterness of PROP.
    [Show full text]
  • G Protein-Coupled Receptors
    Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences,
    [Show full text]
  • Table S4. RAE Analysis of Dedifferentiated Liposarcoma
    Table S4. RAE analysis of dedifferentiated liposarcoma Model Chromosome Region start Region end Size q value freqX0* # genes genes Amp 1 57809872 60413476 2603605 0.00026 34.6 10 DAB1,RPS26P15,OMA1,TACSTD2,MYSM1,JUN,FGGY,HOOK1,CYP2J2,C1orf87 Amp 1 158619146 158696968 77823 0.053 25 1 VANGL2 Amp 1 158883523 158922841 39319 0.081 23.1 2 SLAMF1,CD48 Amp 1 162042586 162118557 75972 0.072 25 0 [Nearest:NUF2] Amp 1 162272460 162767627 495168 0.017 26.9 0 [Nearest:PBX1] Amp 1 165486554 165532374 45821 0.057 25 1 POU2F1 Amp 1 167138282 167483267 344986 0.024 26.9 2 ATP1B1,NME7 Amp 1 167612872 167708844 95973 0.041 25 3 BLZF1,C1orf114,SLC19A2 Amp 1 167728199 167808161 79963 0.076 21.2 1 F5 Amp 1 168436370 169233893 797524 0.018 26.9 3 GORAB,PRRX1,C1orf129 Amp 1 169462231 170768440 1306210 1.3E-06 38.5 10 FMO1,FMO4,TOP1P1,BAT2D1,MYOC,VAMP4,METTL13,DNM3,C1orf105,PIGC Amp 1 171026247 171291427 265181 0.015 26.9 1 TNFSF18 Del 1 201860394 202299299 438906 0.0047 25 6 ATP2B4,SNORA77,LAX1,ZC3H11A,SNRPE,C1orf157 Del 1 210909187 212021116 1111930 0.017 19.2 8 BATF3,NSL1,TATDN3,C1orf227,FLVCR1,VASH2,ANGEL2,RPS6KC1 Del 1 215937857 216049214 111358 0.079 23.1 1 SPATA17 Del 1 218237257 218367476 130220 0.0063 26.9 3 EPRS,BPNT1,IARS2 Del 1 222100886 222727238 626353 5.2E-05 32.7 5 FBXO28,DEGS1,NVL,CNIH4,WDR26 Del 1 223166548 224519805 1353258 0.0063 26.9 15 DNAH14,LBR,ENAH,SRP9,EPHX1,TMEM63A,LEFTY1,PYCR2,LEFTY2,C1orf55,H3F3A,LOC440926 ,ACBD3,MIXL1,LIN9 Del 1 225283136 225374166 91031 0.054 23.1 1 CDC42BPA Del 1 227278990 229012661 1733672 0.091 21.2 13 RAB4A,SPHAR,C1orf96,ACTA1,NUP133,ABCB10,TAF5L,URB2,GALNT2,PGBD5,COG2,AGT,CAP
    [Show full text]
  • E2017138 (PDF)
    History of Modern Biomedicine Research Group School of History, Queen Mary University of London Mile End Road, London E1 4NS website: www.histmodbiomed.org VIDEO INTERVIEW TRANSCRIPT Sanger, Gareth: transcript of a video interview (08-Dec-2016) Interviewer: Tilli Tansey Transcriber: Debra Gee Editors: Tilli Tansey, Apostolos Zarros Date of publication: 05-May-2017 Date and place of interview: 08-Dec-2016; Queen Mary University of London Publisher: Queen Mary University of London Collection: History of Modern Biomedicine Interviews (Digital Collection) Reference: e2017138 Number of pages: 10 DOI: 10.17636/01022654 Acknowledgments: The project management of Mr Adam Wilkinson and the technical support (filming and production) of Mr Alan Yabsley are gratefully acknowledged. The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity (no. 210183). The current interview has been funded by the Wellcome Trust Strategic Award entitled “Makers of modern biomedicine: testimonies and legacy” (2012-2017; awarded to Professor Tilli Tansey). Citation: Tansey E M (intvr); Tansey E M, Zarros A (eds) (2017) Sanger, Gareth: transcript of a video interview (08-Dec- 2016). History of Modern Biomedicine Interviews (Digital Collection), item e2017138. London: Queen Mary University of London. Related resources: items 2017139 - 2017152, History of Modern Biomedicine Interviews (Digital Collection) Note: Video interviews are conducted following standard oral history methodology, and have received ethical approval (reference QMREC 0642). Video interview transcripts are edited only for clarity and factual accuracy. Related material has been deposited in the Wellcome Library. © The Trustee of the Wellcome Trust, London, 2017 History of Modern Biomedicine Interviews (Digital Collection) - Sanger, G e2017138 | 2 Sanger, Gareth: transcript of a video interview (08-Dec-2016)* Biography: Professor Gareth Sanger BSc PhD DSc FBPhS FRSB (b.
    [Show full text]
  • Ep 2391711 B1
    (19) TZZ ¥____T (11) EP 2 391 711 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 5/00 (2006.01) C12N 5/07 (2010.01) 08.04.2015 Bulletin 2015/15 G01N 33/50 (2006.01) (21) Application number: 10736548.8 (86) International application number: PCT/US2010/022781 (22) Date of filing: 01.02.2010 (87) International publication number: WO 2010/088633 (05.08.2010 Gazette 2010/31) (54) NOVEL CELL LINES AND METHODS NEUE ZELLLINIEN UND VERFAHREN NOUVELLES LIGNÉES CELLULAIRES ET PROCÉDÉS (84) Designated Contracting States: • SAWCHUK, Dennis AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Fanwood, NJ 07023 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • SHAH, Purvi, Manoj PT RO SE SI SK SM TR North Brunswick, NJ 08902 (US) (30) Priority: 02.02.2009 US 149311 P (74) Representative: Jennings, Tara Romaine 02.02.2009 US 149318 P FRKelly 02.02.2009 US 149321 P 27 Clyde Road 31.07.2009 US 230536 P Ballsbridge 19.08.2009 US 235181 P Dublin 4 (IE) 02.02.2009 US 149324 P (56) References cited: (43) Date of publication of application: WO-A2-2009/102569 US-A1- 2005 032 158 07.12.2011 Bulletin 2011/49 US-A1- 2006 147 937 US-A1- 2008 262 087 (60) Divisional application: • TOYONO ET AL: "CCAAT/Enhancer-binding 15156204.8 protein beta regulates expression of human T1R3 taste receptor gene in the bile duct carcinoma cell (73) Proprietor: Chromocell Corporation line, HuCCT1", BIOCHIMICA ET BIOPHYSICA North Brunswick, NJ 08902 (US) ACTA .
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. List of genes that encode proteins contianing cell surface epitopes and are represented on Agilent human 1A V2 microarray chip (2,177 genes) Agilent Probe ID Gene Symbol GenBank ID UniGene ID A_23_P103803 FCRH3 AF459027 Hs.292449 A_23_P104811 TREH AB000824 Hs.129712 A_23_P105100 IFITM2 X57351 Hs.174195 A_23_P107036 C17orf35 X51804 Hs.514009 A_23_P110736 C9 BC020721 Hs.1290 A_23_P111826 SPAM1 NM_003117 Hs.121494 A_23_P119533 EFNA2 AJ007292 No-Data A_23_P120105 KCNS3 BC004987 Hs.414489 A_23_P128195 HEM1 NM_005337 Hs.182014 A_23_P129332 PKD1L2 BC014157 Hs.413525 A_23_P130203 SYNGR2 AJ002308 Hs.464210 A_23_P132700 TDGF1 X14253 Hs.385870 A_23_P1331 COL13A1 NM_005203 Hs.211933 A_23_P138125 TOSO BC006401 Hs.58831 A_23_P142830 PLA2R1 U17033 Hs.410477 A_23_P146506 GOLPH2 AF236056 Hs.494337 A_23_P149569 MG29 No-Data No-Data A_23_P150590 SLC22A9 NM_080866 Hs.502772 A_23_P151166 MGC15619 BC009731 Hs.334637 A_23_P152620 TNFSF13 NM_172089 Hs.54673 A_23_P153986 KCNJ3 U39196 No-Data A_23_P154855 KCNE1 NM_000219 Hs.121495 A_23_P157380 KCTD7 AK056631 Hs.520914 A_23_P157428 SLC10A5 AK095808 Hs.531449 A_23_P160159 SLC2A5 BC001820 Hs.530003 A_23_P162162 KCTD14 NM_023930 Hs.17296 A_23_P162668 CPM BC022276 Hs.334873 A_23_P164341 VAMP2 AL050223 Hs.25348 A_23_P165394 SLC30A6 NM_017964 Hs.552598 A_23_P167276 PAQR3 AK055774 Hs.368305 A_23_P170636 KCNH8 AY053503 Hs.475656 A_23_P170736 MMP17 NM_016155 Hs.159581 A_23_P170959 LMLN NM_033029 Hs.518540 A_23_P19042 GABRB2 NM_021911 Hs.87083 A_23_P200361 CLCN6 X83378 Hs.193043 A_23_P200710 PIK3C2B
    [Show full text]